01—Abstract
Summary
Summary of the 8-K filed January 15, 2026. Cited figures are marked; the original filing is the authoritative source.
On January 15, 2026, Boston Scientific (BSX) announced a definitive agreement to acquire Penumbra, Inc. (PEN), a leader in mechanical thrombectomy and neurovascular devices, at $374a per share, implying an enterprise value of approximately $14.5 billion (about $15 billion for fully diluted equity, net of roughly $470 million of Penumbra net cash).
Consideration is elected by Penumbra holders as $374b cash or 3.8721 BSX shares, prorated so the total is roughly 73% cash and 27% stock. BSX expects to fund the approximately $11 billion cash portion with cash on hand and new debt, and the stock component implies roughly 41 million new BSX shares, fixed at signing. Strategically, the deal gives Boston Scientific a scaled entry into mechanical thrombectomy, embolization, and neurovascular, which management describes as large, underserved segments with a weighted-average market growth rate of about 11%.
Penumbra expects fourth-quarter 2025 reported revenue growth of roughly 21.4% to 22.0% and full-year 2025 revenue of about $1.4 billionc (17.3% to 17.5% growth), with preliminary gross margin near 68% and operating margin near 13.5%. Financially, BSX expects the deal to be dilutive to adjusted EPS by $0.06 to $0.08 in the first full year after closing, neutral to slightly accretive in year two, and more accretive thereafter; GAAP EPS will be dilutive for longer due to amortization and acquisition-related charges.
The transaction requires Penumbra stockholder approval and customary regulatory clearances and is expected to close in 2026. Investors should monitor financing terms (the nature of the new debt is still to be finalized), leverage and credit-rating impact, integration execution, and the realization of the projected growth and margin contributions.
02—Key points
Key Highlights
- Deal value: $374 per Penumbra share, roughly $15 billion fully diluted equity value and about $14.5 billion enterprise value.
- Consideration mix: holders can elect $374 cash or 3.8721 BSX shares, prorated to about 73% cash and 27% stock; Penumbra CEO Adam Elsesser intends to take all stock and will join the BSX board at close.
- Financing: about $11 billion cash portion to be funded with cash on hand and new debt, with the debt structure still to be finalized; BSX expects to maintain strong credit ratings.
- Equity issuance: roughly 41 million new BSX shares (about $4 billion of stock), with the exchange ratio fixed at signing based on the 10-day VWAP ending January 13, 2026.
- EPS impact: expected adjusted EPS dilution of $0.06 to $0.08 in the first full year post-close, neutral to slightly accretive in year two, and more accretive thereafter; GAAP EPS dilutive for longer.
- Target fundamentals: Penumbra projects FY2025 revenue of about $1.4 billion (17.3% to 17.5% growth), Q4 growth of 21.4% to 22.0%, gross margin of about 68%, and operating margin of about 13.5% (preliminary, unaudited).
- Strategic rationale: entry into mechanical thrombectomy, peripheral embolization, and neurovascular markets, with management citing a weighted-average market growth rate of about 11% and cross-selling leverage through BSX's global footprint.
- Timing and conditions: closing expected in 2026, subject to Penumbra stockholder approval, regulatory approvals, and other customary conditions.
03—Questions
Frequently Asked Questions
What is Boston Scientific paying for Penumbra and how is it structured?
Boston Scientific is paying $374 per Penumbra share, valuing the company at about $15 billion in fully diluted equity and about $14.5 billion in enterprise value. Penumbra holders can elect either $374 in cash or 3.8721 BSX shares per Penumbra share, subject to proration so the total mix is roughly 73% cash and 27% stock.
How will Boston Scientific finance the cash portion of the deal?
The approximately $11 billion cash component will be funded through a combination of cash on hand and new debt. The specific nature and terms of the debt will be finalized between signing and closing, and management says it expects to maintain strong credit ratings.
How will the deal affect Boston Scientific's earnings per share?
On an adjusted basis, the deal is expected to be $0.06 to $0.08 dilutive to EPS in the first full year after closing, neutral to slightly accretive in the second year, and more accretive thereafter. GAAP EPS will be dilutive for a longer period because of amortization expense and acquisition-related charges.
What does Penumbra bring to Boston Scientific?
Penumbra is a leading thrombectomy company with products for pulmonary embolism, stroke, deep vein thrombosis, and acute limb ischemia, plus embolization and neurovascular offerings. Penumbra expects FY2025 revenue of about $1.4 billion, growing roughly 17% to 18%, with high-growth adjacent segments that management believes will be accretive to Boston Scientific's growth profile.
What are the main risks and remaining steps before the deal closes?
Closing requires Penumbra stockholder approval, required regulatory clearances, and other customary conditions, and is expected in 2026. Key risks include regulatory outcomes, integration of Penumbra's operations, business disruption, the final structure of the new debt, and whether the expected growth and margin benefits materialize.
04—Continue